Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FlyteHealth vs T2D.com

FlyteHealth
Graded #364

Higher grade

vs+5.600000000000001
T2D.com
Graded #474

Lower grade

The verdict

FlyteHealth takes it — 58.6/100 to 53/100.

FlyteHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FlyteHealth is an obesity-medicine telehealth platform distributed mainly through employers, payers, and health plans, with care led by board-certified obesity-medicine physicians plus nurse practitioners,…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFlyteHealth +16
45
29
Dose & formulationT2D.com +24
40
64
Clinical oversightFlyteHealth +14
83
69
Labs & monitoringFlyteHealth +21
73
52
FulfillmentFlyteHealth +4
62
58
Contract termsEven
55
55
FlyteHealth · left barT2D.com · right bar

The numbers

MetricFlyteHealthT2D.com
WeighScore58.6/10053/100
GradeCC
Scorecard rank#364#474
SemaglutideNot disclosed$999/mo (starting dose, compounded)
TirzepatideNot disclosed$999/mo (starting dose, compounded)
CoverageCoverage not published1 state
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
FlyteHealth

Graded #364 · C

Strengths

  • Care led by board-certified obesity-medicine physicians
  • Multidisciplinary team with NPs, dietitians, and care coordinators
  • Published outcomes of about 13 to 16 percent weight loss over 12 months
  • High GLP-1 medication adherence (around 86 percent in reported data)
  • Comprehensive cardiometabolic care beyond GLP-1 alone

Where it loses points

  • Distributed primarily via employers, payers, and health plans, not direct cash-pay
  • Access is largely gated behind employer or plan sponsorship
  • GLP-1 is prescribed only when appropriate, not guaranteed
  • Self-pay pricing is not publicly listed (contact required)
  • Less suited to consumers wanting fast direct-to-door GLP-1
T2D.com

Graded #474 · C

Strengths

  • Built specifically for type 2 diabetic and pre-diabetic patients
  • Integrated service — prescriber, pharmacy, and delivery handled in one flow
  • Offers both compounded semaglutide and compounded tirzepatide
  • Temperature-controlled home delivery via UPS or FedEx
  • Ongoing prescriber monitoring and support included

Where it loses points

  • No pricing published on the public website — must register to see costs
  • No states list published on the site
  • Newer brand with limited independent reviews
  • Compounded only — no brand-name Ozempic, Wegovy, or Mounjaro

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard